Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The polyclonal pathogen and antigen repertoire refers to the broad collection of microbial and self-antigens targeted by polyvalent immunoglobulin preparations, such as Intravenous Immunoglobulin (IVIG). These preparations are derived from the plasma of thousands of healthy donors and contain a diverse array of IgG antibodies that recognize a wide spectrum of bacterial, viral, and fungal pathogens, as well as various toxins and autoantigens. By providing this broad repertoire of antibodies, these therapies offer passive immunity to immunocompromised patients and modulate the immune system in individuals with autoimmune or inflammatory disorders. In clinical practice, targeting this repertoire is essential for treating primary and secondary immunodeficiencies, where it replaces missing antibodies to prevent infections. Additionally, in autoimmune conditions like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Immune Thrombocytopenia (ITP), the polyclonal antibodies interact with Fc receptors, neutralize autoantibodies, and suppress inflammatory cytokines to restore immune balance. The therapeutic efficacy of drugs hitting this target is monitored through serum IgG levels and the resolution of clinical symptoms, while safety monitoring focuses on infusion reactions and potential renal or thromboembolic complications.
Neutralization of pathogens and toxins, opsonization for phagocytosis, complement-mediated lysis, modulation of Fc receptors, neutralization of autoantibodies, and modulation of cytokine production.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyclonal pathogen and antigen repertoire.